Cargando…

Inhibition of α-, β- and γ-carbonic anhydrases from the pathogenic bacterium Vibrio cholerae with aromatic sulphonamides and clinically licenced drugs – a joint docking/molecular dynamics study

The binding mode of aromatic sulphonamides and clinically licenced drugs to the three carbonic anhydrase (CA, EC 4.2.1.1) isoforms from the human pathogen V. cholerae was here thouroghly characterised by a joint docking and molecular dynamics in silico protocol. In fact, VchCA, VchCAβ, and VchCAγ ar...

Descripción completa

Detalles Bibliográficos
Autores principales: Bonardi, Alessandro, Nocentini, Alessio, Osman, Sameh Mohamed, Alasmary, Fatmah Ali, Almutairi, Tahani Mazyad, Abdullah, Dalal Saied, Gratteri, Paola, Supuran, Claudiu T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7822066/
https://www.ncbi.nlm.nih.gov/pubmed/33472446
http://dx.doi.org/10.1080/14756366.2020.1862102
_version_ 1783639554194931712
author Bonardi, Alessandro
Nocentini, Alessio
Osman, Sameh Mohamed
Alasmary, Fatmah Ali
Almutairi, Tahani Mazyad
Abdullah, Dalal Saied
Gratteri, Paola
Supuran, Claudiu T.
author_facet Bonardi, Alessandro
Nocentini, Alessio
Osman, Sameh Mohamed
Alasmary, Fatmah Ali
Almutairi, Tahani Mazyad
Abdullah, Dalal Saied
Gratteri, Paola
Supuran, Claudiu T.
author_sort Bonardi, Alessandro
collection PubMed
description The binding mode of aromatic sulphonamides and clinically licenced drugs to the three carbonic anhydrase (CA, EC 4.2.1.1) isoforms from the human pathogen V. cholerae was here thouroghly characterised by a joint docking and molecular dynamics in silico protocol. In fact, VchCA, VchCAβ, and VchCAγ are crucial in the pathogen life cycle and growth and represent innovative targets to fight V. cholerae proliferation overcoming the spreading chemoresistance to the available drugs. A set of 40 sulphonamides/sulfamates VchCAs inhibitors was studied using the proteins homology built 3 D models unveiling the key and stable interactions responsible for a potent CA inhibition. This study has the aim to offer insights and guidelines for the future rational design of potent and selective inhibitors targeting CA isoforms from V. cholerae or other human pathogens.
format Online
Article
Text
id pubmed-7822066
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Taylor & Francis
record_format MEDLINE/PubMed
spelling pubmed-78220662021-01-29 Inhibition of α-, β- and γ-carbonic anhydrases from the pathogenic bacterium Vibrio cholerae with aromatic sulphonamides and clinically licenced drugs – a joint docking/molecular dynamics study Bonardi, Alessandro Nocentini, Alessio Osman, Sameh Mohamed Alasmary, Fatmah Ali Almutairi, Tahani Mazyad Abdullah, Dalal Saied Gratteri, Paola Supuran, Claudiu T. J Enzyme Inhib Med Chem Research Paper The binding mode of aromatic sulphonamides and clinically licenced drugs to the three carbonic anhydrase (CA, EC 4.2.1.1) isoforms from the human pathogen V. cholerae was here thouroghly characterised by a joint docking and molecular dynamics in silico protocol. In fact, VchCA, VchCAβ, and VchCAγ are crucial in the pathogen life cycle and growth and represent innovative targets to fight V. cholerae proliferation overcoming the spreading chemoresistance to the available drugs. A set of 40 sulphonamides/sulfamates VchCAs inhibitors was studied using the proteins homology built 3 D models unveiling the key and stable interactions responsible for a potent CA inhibition. This study has the aim to offer insights and guidelines for the future rational design of potent and selective inhibitors targeting CA isoforms from V. cholerae or other human pathogens. Taylor & Francis 2021-01-20 /pmc/articles/PMC7822066/ /pubmed/33472446 http://dx.doi.org/10.1080/14756366.2020.1862102 Text en © 2021 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Paper
Bonardi, Alessandro
Nocentini, Alessio
Osman, Sameh Mohamed
Alasmary, Fatmah Ali
Almutairi, Tahani Mazyad
Abdullah, Dalal Saied
Gratteri, Paola
Supuran, Claudiu T.
Inhibition of α-, β- and γ-carbonic anhydrases from the pathogenic bacterium Vibrio cholerae with aromatic sulphonamides and clinically licenced drugs – a joint docking/molecular dynamics study
title Inhibition of α-, β- and γ-carbonic anhydrases from the pathogenic bacterium Vibrio cholerae with aromatic sulphonamides and clinically licenced drugs – a joint docking/molecular dynamics study
title_full Inhibition of α-, β- and γ-carbonic anhydrases from the pathogenic bacterium Vibrio cholerae with aromatic sulphonamides and clinically licenced drugs – a joint docking/molecular dynamics study
title_fullStr Inhibition of α-, β- and γ-carbonic anhydrases from the pathogenic bacterium Vibrio cholerae with aromatic sulphonamides and clinically licenced drugs – a joint docking/molecular dynamics study
title_full_unstemmed Inhibition of α-, β- and γ-carbonic anhydrases from the pathogenic bacterium Vibrio cholerae with aromatic sulphonamides and clinically licenced drugs – a joint docking/molecular dynamics study
title_short Inhibition of α-, β- and γ-carbonic anhydrases from the pathogenic bacterium Vibrio cholerae with aromatic sulphonamides and clinically licenced drugs – a joint docking/molecular dynamics study
title_sort inhibition of α-, β- and γ-carbonic anhydrases from the pathogenic bacterium vibrio cholerae with aromatic sulphonamides and clinically licenced drugs – a joint docking/molecular dynamics study
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7822066/
https://www.ncbi.nlm.nih.gov/pubmed/33472446
http://dx.doi.org/10.1080/14756366.2020.1862102
work_keys_str_mv AT bonardialessandro inhibitionofabandgcarbonicanhydrasesfromthepathogenicbacteriumvibriocholeraewitharomaticsulphonamidesandclinicallylicenceddrugsajointdockingmoleculardynamicsstudy
AT nocentinialessio inhibitionofabandgcarbonicanhydrasesfromthepathogenicbacteriumvibriocholeraewitharomaticsulphonamidesandclinicallylicenceddrugsajointdockingmoleculardynamicsstudy
AT osmansamehmohamed inhibitionofabandgcarbonicanhydrasesfromthepathogenicbacteriumvibriocholeraewitharomaticsulphonamidesandclinicallylicenceddrugsajointdockingmoleculardynamicsstudy
AT alasmaryfatmahali inhibitionofabandgcarbonicanhydrasesfromthepathogenicbacteriumvibriocholeraewitharomaticsulphonamidesandclinicallylicenceddrugsajointdockingmoleculardynamicsstudy
AT almutairitahanimazyad inhibitionofabandgcarbonicanhydrasesfromthepathogenicbacteriumvibriocholeraewitharomaticsulphonamidesandclinicallylicenceddrugsajointdockingmoleculardynamicsstudy
AT abdullahdalalsaied inhibitionofabandgcarbonicanhydrasesfromthepathogenicbacteriumvibriocholeraewitharomaticsulphonamidesandclinicallylicenceddrugsajointdockingmoleculardynamicsstudy
AT gratteripaola inhibitionofabandgcarbonicanhydrasesfromthepathogenicbacteriumvibriocholeraewitharomaticsulphonamidesandclinicallylicenceddrugsajointdockingmoleculardynamicsstudy
AT supuranclaudiut inhibitionofabandgcarbonicanhydrasesfromthepathogenicbacteriumvibriocholeraewitharomaticsulphonamidesandclinicallylicenceddrugsajointdockingmoleculardynamicsstudy